Candidiasis, Chronic Mucocutaneous
"Candidiasis, Chronic Mucocutaneous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A clinical syndrome characterized by development, usually in infancy or childhood, of a chronic, often widespread candidiasis of skin, nails, and mucous membranes. It may be secondary to one of the immunodeficiency syndromes, inherited as an autosomal recessive trait, or associated with defects in cell-mediated immunity, endocrine disorders, dental stomatitis, or malignancy.
MeSH Number(s)
C01.539.800.200.100
C01.703.160.165
C01.703.295.165
C17.800.838.208.165
Concept/Terms
Candidiasis, Chronic Mucocutaneous- Candidiasis, Chronic Mucocutaneous
- Candidiases, Chronic Mucocutaneous
- Chronic Mucocutaneous Candidiases
- Chronic Mucocutaneous Candidiasis
- Mucocutaneous Candidiases, Chronic
- Mucocutaneous Candidiasis, Chronic
Below are MeSH descriptors whose meaning is more general than "Candidiasis, Chronic Mucocutaneous".
Below are MeSH descriptors whose meaning is more specific than "Candidiasis, Chronic Mucocutaneous".
This graph shows the total number of publications written about "Candidiasis, Chronic Mucocutaneous" by people in Harvard Catalyst Profiles by year, and whether "Candidiasis, Chronic Mucocutaneous" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1996 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
Below are the most recent publications written about "Candidiasis, Chronic Mucocutaneous" by people in Profiles.
-
Emapalumab as bridge to hematopoietic cell transplant for STAT1 gain-of-function mutations. J Allergy Clin Immunol. 2023 09; 152(3):815-817.
-
Aberrant type 1 immunity drives susceptibility to mucosal fungal infections. Science. 2021 01 15; 371(6526).
-
Novel CARD9 mutation in a patient with chronic invasive dermatophyte infection (tinea profunda). J Cutan Pathol. 2020 Feb; 47(2):166-170.
-
Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol. 2017 May; 139(5):1629-1640.e2.
-
Chronic mucocutaneous candidiasis associated with an SH2 domain gain-of-function mutation that enhances STAT1 phosphorylation. J Allergy Clin Immunol. 2016 07; 138(1):297-299.
-
The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1. J Clin Immunol. 2016 Jan; 36(1):73-84.
-
IMMUNODEFICIENCIES. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations. Science. 2015 Aug 07; 349(6248):606-613.
-
Two novel gain-of-function mutations of STAT1 responsible for chronic mucocutaneous candidiasis disease: impaired production of IL-17A and IL-22, and the presence of anti-IL-17F autoantibody. J Immunol. 2014 Nov 15; 193(10):4880-7.
-
Skin microbiome imbalance in patients with STAT1/STAT3 defects impairs innate host defense responses. J Innate Immun. 2014; 6(3):253-62.
-
Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans. Nat Commun. 2013; 4:1342.